Authors
McWilliam, AlanPalma, G
Abravan, Azadeh
Acosta, O
Appelt, A
Aznar, M
Monti, S
Onjukka, E
Panettieri, V
Placidi, L
Rancati, T
Osorio, EV
Witte, M
Cella, L
Affiliation
The Division of Cancer Sciences, The University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UKIssue Date
2023
Metadata
Show full item recordAbstract
Voxel-based analysis (VBA) allows the full, 3-dimensional, dose distribution to be considered in radiotherapy outcome analysis. This provides new insights into anatomical variability of pathophysiology and radiosensitivity by removing the need for a priori definition of organs assumed to drive the dose response associated with patient outcomes. This approach may offer powerful biological insights demonstrating the heterogeneity of the radiobiology across tissues and potential associations of the radiotherapy dose with further factors. As this methodological approach becomes established, consideration needs to be given to translating VBA results to clinical implementation for patient benefit. Here, we present a comprehensive roadmap for VBA clinical translation. Technical validation needs to demonstrate robustness to methodology, where clinical validation must show generalisability to external datasets and link to a plausible pathophysiological hypothesis. Finally, clinical utility requires demonstration of potential benefit for patients in order for successful translation to be feasible. For each step on the roadmap, key considerations are discussed and recommendations provided for best practice.Citation
McWilliam A, Palma G, Abravan A, Acosta O, Appelt A, Aznar M, et al. Voxel-based analysis: Roadmap for clinical translation. RADIOTHERAPY AND ONCOLOGY. 2023 NOV;188. PubMed PMID: WOS:001081469200001. English.Journal
Radiotherapy And OncologyDOI
10.1016/j.radonc.2023.109868PubMed ID
37683811Type
Articleae974a485f413a2113503eed53cd6c53
10.1016/j.radonc.2023.109868
Scopus Count
Collections
Related articles
- The sensitivity of radiobiological models in carbon ion radiotherapy (CIRT) and its consequences on the clinical treatment plan: Differences between LEM and MKM models.
- Authors: Góra J, Grosshagauer S, Fossati P, Mumot M, Stock M, Schafasand M, Carlino A
- Issue date: 2024 Jul
- Patient-specific voxel-level dose prescription for prostate cancer radiotherapy considering tumor cell density and grade distribution.
- Authors: Zhao Y, Haworth A, Reynolds HM, Her EJ, Sun Y, Finnegan R, Rowshanfarzad P, Ebert MA
- Issue date: 2023 Jun
- Towards biologically conformal radiation therapy (BCRT): selective IMRT dose escalation under the guidance of spatial biology distribution.
- Authors: Yang Y, Xing L
- Issue date: 2005 Jun
- The modelled benefits of individualizing radiotherapy patients' dose using cellular radiosensitivity assays with inherent variability.
- Authors: Mackay RI, Hendry JH
- Issue date: 1999 Jan
- Inter-patient image registration algorithms to disentangle regional dose bioeffects.
- Authors: Monti S, Pacelli R, Cella L, Palma G
- Issue date: 2018 Mar 20